Understanding Patent Infringement: What Founders Need to Know

The Day Kodak Learned That 'Similar' Is Not a Defense

In April 1976, Kodak launched its instant camera line — a product its engineers had spent years developing, deliberately engineering around every Polaroid patent they could identify. They believed they had done the work. Eleven years later, a federal court ruled that Kodak had infringed seven Polaroid patents and ordered it to pay $909 million in damages, exit the instant-photography market entirely, and compensate approximately 700,000 customers whose cameras were now useless. The engineers had identified the wrong boundary. They had designed around Polaroid's product features, not Polaroid's patent claims — and those two things are rarely the same.

That gap is where most founder-level infringement disasters originate. Patent infringement is not determined by comparing two products. It is determined by comparing one product against the text of a patent claim, element by element. Understanding that distinction — and building your IP strategy around it, not around it — is the difference between a defensible market position and a nine-figure liability.

What Infringement Actually Means: The All-Elements Rule

Under 35 U.S.C. §271(a), infringement occurs when a party makes, uses, sells, offers for sale, or imports a patented invention in the United States without authorization. The statute sounds simple. The doctrine that implements it is not.

Courts apply the all-elements rule: a product or process infringes a patent claim only if it practices every element recited in that claim. Remove a single element from your product, and you have designed around the claim. This is why Kodak's engineers thought they were safe — they had removed or altered specific features. What they missed is that patent claims often recite functional elements, not structural ones. Polaroid's claims described what the photographic chemistry accomplished, not the precise molecular pathway it used. Kodak's different chemistry accomplished the same function, and that was enough.

The doctrine that extends the all-elements rule into functional territory is the doctrine of equivalents. Even when a product avoids the literal language of a claim, it can still infringe if the differing element performs substantially the same function, in substantially the same way, to achieve substantially the same result. The Kodak engineers optimized for structural dissimilarity. The court evaluated functional equivalence. These are different tests with different outcomes.

For founders, this creates a clearance problem that cannot be solved by reading patents the way a layperson reads them. You must read the claims — specifically the independent claims — and then evaluate not whether your product looks like the patented product, but whether your product practices each claimed element, either literally or equivalently.

The Claim Mirror Effect: Why Your Broadest Weapon Is Also Your Biggest Risk

Here is the strategic tension that most IP advisors underemphasize: the decision about how broadly to draft your own patent claims is not purely offensive. It is simultaneously defensive — and the two objectives pull in opposite directions.

Broad independent claims — claims with fewer elements, each described at high abstraction — maximize your infringement coverage against competitors. A competitor who adds a feature not recited in your claim still infringes; the all-elements rule works in your favor precisely because your claim recites fewer elements. But those same broad claims are more likely to read on prior art held by incumbents, making you a cleaner infringement target yourself.

Narrow claims — loaded with specific elements during prosecution to survive a prior-art rejection — survive prosecution and reduce your clearance exposure. But a competitor who removes or substitutes a single specific element has now designed around your claim entirely. You have handed them the corridor.

This is the Claim Mirror Effect: claim breadth is a two-sided mirror. Every word added to narrow a claim reduces your clearance risk while simultaneously widening the design-around space available to competitors. Sophisticated patent strategy does not choose a single breadth level — it drafts a lattice of claims, with broad independent claims anchoring the offense, and progressively narrower dependent claims as fallback positions that competitors cannot simultaneously invalidate or design around all at once. Kodak's litigation fate would have been different if Polaroid had drafted only narrow claims. It was Polaroid's independent claim breadth — covering the functional outcome of the chemistry — that survived every design-around attempt Kodak made.

The Three Infringement Scenarios Founders Actually Face

Scenario 1: You Are the Accused Infringer

A cease-and-desist letter lands in your inbox from a non-practicing entity or an incumbent. The standard founder mistake is to panic, respond quickly, or — worse — to simply stop the allegedly infringing activity without analysis. All three responses can be costly. Stopping the activity without a formal non-infringement opinion may constitute an implicit admission in subsequent litigation. Responding quickly without counsel waives negotiating leverage. Panicking leads to licensing agreements signed under urgency that grant royalty rates far above market.

The correct first move is a freedom-to-operate (FTO) analysis — a formal claim-by-claim comparison of the asserted patent against your product or process, conducted by a patent attorney who can render a written opinion. A credible non-infringement opinion does two things: it gives you an evidentiary basis to continue operations without willful-infringement exposure, and it shows a potential licensor that you will not settle cheaply. Under 35 U.S.C. §284, a court can award up to treble damages for willful infringement. Under §285, it can award attorney fees in exceptional cases. The written opinion is your shield against both.

If the FTO analysis reveals actual infringement risk, you have three options: design around the claim (remove or substitute a claim element), negotiate a license, or challenge the patent's validity through inter partes review (IPR) at the USPTO — which costs roughly $35,000–$60,000 in filing and counsel fees but is significantly cheaper than district court litigation and carries a historically favorable invalidation rate for petitioners.

Scenario 2: You Are the Patent Holder Enforcing Your Rights

Discovering that a competitor's product practices your claims requires the same analytical discipline, applied in reverse. Before sending a cease-and-desist letter, conduct the same element-by-element comparison you would want a defendant to conduct. Asserting a patent without a credible infringement theory exposes you to a §285 fee award — the court's mechanism for sanctioning objectively unreasonable assertions.

Polaroid's sustained litigation advantage in the Kodak case came from the specificity of its infringement theory. Its engineers and attorneys had mapped each Kodak product against each claim element before filing suit. That preparation produced a coherent, documented theory that survived twelve years of litigation.

The enforcement decision also requires understanding your claim's geographic scope. A U.S. patent only covers activities within the United States. A competitor manufacturing abroad and selling into the U.S. may be liable under §271(a) for the importation and sale, but the offshore manufacturing act itself is not directly actionable unless you hold patents in those jurisdictions. Founders who file only U.S. patents and then discover that a copycat has replicated their product in a country where they have no coverage have learned this lesson expensively.

Scenario 3: Your Employees and Contractors Are the Exposure Point

Two infringement vectors that founders consistently underweight: prior employer IP and co-inventor disclosure failures. If a founding engineer came from an incumbent competitor and developed the core technology within 12–18 months of departure, the prior employer may assert that the invention belongs to them under a prior assignment agreement. This is not a hypothetical — it is a standard diligence question that every Series A investor's IP counsel will investigate, and a cloud on title can delay or kill a financing.

Co-inventor disclosure failures create a parallel problem. Under 35 U.S.C. §102(f), a patent is invalid if it fails to name all actual inventors. If a contractor or advisor made a non-trivial contribution to a claimed invention and is not listed, the patent is vulnerable to invalidity challenge — by a defendant in infringement litigation, or by the unnamed inventor themselves. Have every contributor sign an IP assignment agreement before they start work, not after.

The Public Disclosure Trap: Your Own Timeline as Prior Art

The America Invents Act preserved a one-year grace period for inventors who publicly disclose their own invention before filing — but that grace period is narrower than founders assume. It applies only in the United States. In Europe, Japan, and most other jurisdictions, any public disclosure before the filing date destroys novelty absolutely. A demo at a trade show, a pitch deck shared without an NDA, a published app-store listing — each can permanently foreclose international patent rights from the date of disclosure.

The filing sequence that protects all jurisdictions is: file a U.S. provisional application first (USPTO filing fee: $320 for a small entity, $160 for a micro-entity), then disclose. The provisional establishes a priority date that counts as your filing date in all PCT member countries, preserving your international options for 12 months. After that 12-month window closes, you must file the PCT application or lose the international priority claim. These are hard deadlines — the USPTO does not grant extensions for missed PCT deadlines.

Practical Infringement Clearance: A Founder's Sequence

1. Before product launch, commission a freedom-to-operate search. Budget $3,000–$8,000 for a professional search and $8,000–$20,000 for a formal written opinion from patent counsel. Focus the search on the independent claims of patents owned by direct competitors and category incumbents.
2. Map your product against claim elements, not against competing products. Identify which elements of competitor claims your product practices. If you practice all elements of a single independent claim, you infringe — regardless of how differently your product looks or what additional features it adds.
3. Secure assignments before any technical contributor begins work. Every employee, contractor, and advisor who touches the technology should sign an IP assignment agreement naming your company as assignee. Do not rely on work-for-hire doctrine — it applies only to employees in limited circumstances and does not cover independently conceived inventions.
4. File before you disclose. File at minimum a provisional application before any public demo, press release, or pitch deck shared outside an NDA. Set a calendar reminder for the 12-month provisional expiration date the moment you file.
5. Draft your claims as a lattice, not a single ring. Work with counsel to include at least one broad independent claim, two to three intermediate independent claims, and multiple dependent claims that add specific structural or process limitations as fallback positions. The Claim Mirror Effect means your broad independent claims carry both your highest offensive value and your highest prosecution risk — the dependent claims are your insurance policy.

Frequently Asked Questions

If I change 30% of a competitor's product design, am I safe from infringement?

No — and the "percentage changed" heuristic is one of the most dangerous misconceptions in early-stage IP. Infringement is determined element by element against a patent claim, not by comparing aggregate product similarity. You can change 90% of a product and still infringe if the remaining 10% practices every element of a claim. Conversely, you can remove a single claimed element entirely and avoid literal infringement even if the products look nearly identical. The correct question is not "how much did I change?" but "does my product practice every element of any independent claim?" That question requires reading the claims, not the products.

Can a competitor invalidate my patent as a defense to infringement — and what does that do to my valuation?

Yes, and this is a primary litigation strategy for well-resourced defendants. An infringement defendant can challenge your patent's validity through inter partes review (IPR) at the USPTO or through invalidity counterclaims in district court. If the patent is invalidated, the infringement claim collapses. The investor-facing implication is significant: a patent portfolio that has never been stress-tested by adversarial invalidity analysis carries latent litigation risk that sophisticated acquirers will price into their offers. Pre-acquisition IPR petitions filed by competitors are a documented tactic in patent-heavy M&A processes. Founders should commission a clearance-and-validity analysis of their own patents before any Series B or acquisition process — identifying weak claims proactively, rather than having a buyer's counsel surface them during diligence.

Does a provisional patent application actually protect me from infringement claims by competitors?

No. A provisional application establishes a priority date for your own future patent rights — it does not grant any enforceable rights against infringers, and it is never examined or published by the USPTO. While your provisional is pending, you have no patent rights to enforce. What the provisional does is preserve your ability to file a non-provisional within 12 months and claim that earlier priority date — meaning a competitor who files a similar application after your provisional date cannot use their filing to block yours. The protection runs forward (against later filers) not laterally (against current infringers). Founders who announce "patent pending" based solely on a provisional and believe they are protected against competitive copying are operationally exposed until the non-provisional issues.

If a competitor is infringing my patent from a factory outside the U.S., what leverage do I actually have?

Meaningful leverage, but only through specific channels. Under 35 U.S.C. §271(a), importing a patented product into the United States is itself an act of infringement, regardless of where manufacturing occurred. This means you can sue the importer in U.S. district court and seek an injunction against U.S. importation and sales. You can also file a complaint with the International Trade Commission (ITC) under Section 337, which can result in an exclusion order — effectively a border block on infringing goods — often faster than district court proceedings. What you cannot do is stop the offshore manufacturing act itself without patents in those jurisdictions. The strategic implication: if your technology has global competitive exposure, your patent filing strategy should include PCT filings in the manufacturing jurisdictions your most likely competitors operate from, not just the sales markets you currently serve.

This article is for informational purposes only and does not constitute legal advice. Consult a qualified patent attorney for guidance specific to your situation.